Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Case Report Volume 7 Issue 3

Therapeutic Plasmapheresis in Optical Neuromyelitis

Nolasco-Cardona María Elena1,2*, López-Paz Sisa2, Rivera-Mejía Ronald Virgilio2, Murga Gladys Beatriz1 and Gil José Rodolfo1

1Anatomical and Clinical Pathology, Roosevelt Hospital, Guatemala City, Guatemala
2Universidad Nacional Autónoma de Honduras, Hospital Escuela Universitario, Tegucigalpa, M.D.C, Honduras, Guatemala

*Corresponding Author: Nolasco-Cardona María Elena, Anatomical and Clinical Pathology, Roosevelt Hospital, Guatemala City, Guatemala.

Received: December 30, 2022; Published: February 16, 2023


A 35-year-old, male with gradual bilateral decrease in visual acuity of 5-weeks history of evolution. The campimetry showed 0% of visual field in the left eye and 84% in the right eye, with temporal hemianopsia, imaging studies were performed to rule out any lesion in optic chiasm. Both computerized tomography (CT) and magnetic resonance imaging (MRI) of the brain showed inflammation at the intersection of the optic nerve to the brain (optic neuritis). Likewise, an immunological study was performed to detect the acuaporin-4 antibodies (antiAQP4), being this result positive; so, the diagnosis of optical neuromyelitis (NMO) was concluded. The patient was treated first with steroids at high doses, but no improvement was observed. Therefore, based on the treatment guidelines of the American Apheresis Society (ASFA), Therapeutic Plasma Exchange (TPE)/therapeutic plasmapheresis was decided, giving positive results from the first session.

Keywords: Neuromyelitis Optica; Autoantibodies; Plasmapheresis


  1. Wingerchuk D M., et al. “Revised diagnostic criteria for neuromyelitis optica”. Neurology 10(2006): 1485-1489.
  2. Chiquete E., et al. “Neuromyelitis optica”. Revista Mexicana de Neurociencia 3 (2010): 234-239.
  3. Padmanabhan A., et al. “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis /ASFA: The Eighth Special Issue”. Journal of Clinical Apheresis 3 (2019): 267-268.
  4. Bravo-Lizcano R., et al. “Devic's neuromyelitis optica”. RevClinMedFam2 (2016): 114-118.
  5. Bruscolini A., et al. “Diagnosis and management of neuromyelitis optica spectrum disorders - An update”. Autoimmune Review3 (2018): 195200.
  6. Oertel FC., et al. “Retinal Optical Coherence Tomography in Neuromyelitis Optica”. Neurology: Neuroimmunology and Neuroinflammation 6 (2021): e1068.


Citation: Nolasco-Cardona María Elena., et al. “Therapeutic Plasmapheresis in Optical Neuromyelitis”.Acta Scientific Medical Sciences 7.3 (2023): 133-135.


Copyright: © 2022 Nolasco-Cardona María Elena., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US